Alphabet Inc Class A vs Vaxcyte Inc. Common Stock — how do they compare? Alphabet Inc Class A trades at $341.98 (market cap $4.30T), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Alphabet Inc Class A is far larger — about 409.1× Vaxcyte Inc. Common Stock's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GOOGL | PCVX | |
|---|---|---|
Market Cap | $4.30T | $10.51B |
Volume | 22,270,289 | 2,644,694 |
Sector | Media | Health |
52-Week High | $402.62 | $73.82 |
52-Week Low | $250.46 | $40.32 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.19T | $9.14B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $347.64, down 1.44% today, but maintains strong technical support near $344-$350. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 54.77% net margin. Recent earnings beats and strong analyst consensus support the bullish outlook, with 87% of analysts rating it a Buy. Technical indicators show bullish moving averages but overbought RSI conditions.
Alphabet presents a compelling investment case with strong AI-driven growth, consistent earnings outperformance, and dominant market positioning. Key risks include regulatory scrutiny, competitive pressures in AI, and market volatility. With a consensus price target of $430.96 representing 24% upside potential, the stock offers attractive long-term value despite short-term technical overbought conditions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →